MedTrace Logo

A Clinical Trial to Compare Pharmacokinetics of the "CDFF0318" and "Champix Tab. 1mg"

NCT04631874 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-11-17

No results posted yet for this study

Summary

A Phase 1 Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics after Administration of the "CDFF0318" and "Champix Tab. 1mg (Varenicline tartrate)" in Healthy Male Volunteers

Conditions

  • Smoking Cessation
  • Pharmacokinetics

Interventions

DRUG

CDFF0318, Champix

CDFF0318: Varenicline salt changed Champix: Varenicline tartrate

Sponsors & Collaborators

  • CTC Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Min-Kyu Park · Chungbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-24
Primary Completion
2020-05-01
Completion
2020-05-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04631874 on ClinicalTrials.gov